Results 171 to 180 of about 14,298 (222)

Boosting CAR T cell functionality with oncolytic viruses for the treatment of pediatric diffuse midline gliomas. [PDF]

Mol Ther Oncol
Vazaios K, Tallon-Cobos AC, van Oosterhout LPJ, Waranecki P, Cornel AM, Dautzenberg NMM, van Hoesel M, Forbes C, Nierkens S, Kemp V, Hoeben RC, van der Lugt J, Calkoen FG, Hulleman E.   +13 more
europepmc   +1 more source

Direct Comparison of MRM-MS and PRM-MS Methods for Quantitative Ganglioside Analysis. [PDF]

J Am Soc Mass Spectrom
Sanni A, Koraich A, Nwaiwu J, Delkhosh AS, Mechref Y.   +4 more
europepmc   +1 more source

The Architecture of Immune Escape in Neuroblastoma: Plasticity, Silence and Escape Engineer Immune Blindness. [PDF]

Cells
Subramanian P, Periyasamy L, Mohanvelu S, Aravindan S, Aravindan N.   +4 more
europepmc   +1 more source

GD2-Targeted Minibody-Drug Conjugates Match the Potency of IgG-Based ADCs in a Mouse Cancer Model. [PDF]

Int J Mol Sci
Kalinovsky DV, Titov MM, Kholodenko IV, Kibardin AV, Svirshchevskaya EV, Deyev SM, Kholodenko RV.   +6 more
europepmc   +1 more source

Integrative precision oncology in neuroblastoma: multi-omics biomarkers, molecular targets, and immunotherapeutic strategies. [PDF]

Front Oncol
Singh A, Goel N, Mehndiratta S, Chaudhry A, Kaur M, Swain SK, Prabhakar P, Misra A, Rishi B.   +8 more
europepmc   +1 more source

Pressure-Induced Structural Phase Transition in Gd₂Ce₂O₇ Oxide. [PDF]

Materials (Basel)
Lv T, Qv J, Yan L, Li Y, Tao Q, Zhu P, Wang X.   +6 more
europepmc   +1 more source

Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy

Pediatric and Developmental Pathology, 2017
Neuroblastoma, a malignant neoplasm of the sympathetic nervous system, is one of the most aggressive pediatric cancers. Patients with stage IV high-risk neuroblastoma receive an intensive multimodal therapy ending with an immunotherapy based on a chimeric monoclonal antibody ch14.18.
Tatjana, Terzic, Martine, Cordeau, Sabine, Herblot, Pierre, Teira, Sonia, Cournoyer, Mona, Beaunoyer, Michel, Peuchmaur, Michel, Duval, Herve, Sartelet   +8 more
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Mimotopes of the disialoganglioside GD2 elicit anti-GD2 antibodies recognising GD2 on melanoma cells

Journal of Clinical Oncology, 2006
12505 Background: The disialoganglioside GD2, a carbohydrate antigen, is expressed on all tumors of neuroectodermal origin, including melanoma, sarcoma, neuroblastoma and small cell lung cancer. Due to its specific expression on tumor surfaces, GD2 is an attractive target for immunotherapy.
K. H. Brämswig, A. B. Riemer, E. Förster-Waldl, A. Pollak, C. C. Zielinski, H. Pehamberger, H. N. Lode, O. Scheiner, E. Jensen-Jarolim   +8 more
openaire   +1 more source

Abstract 5115: Novel humanized anti-GD2 antibody inhibits GD2-mediated immunosuppression by targeting GD2+ breast cancer stem-like cells

Cancer Research, 2023
Abstract Background: Breast cancer stem-like cells (BCSCs) are reported to be a major contributing factor for tumor growth and chemotherapy resistance in triple-negative breast cancer (TNBC). We reported that the disialoganglioside GD2 is highly expressed on BCSCs and that targeting GD2 with dinutuximab (chimeric anti-GD2 antibody) in ...
Vivek Anand, Venkatesh Hegde, Maryam Siddiqui, Anudishi Tyagi, Bolutyfe Oderinde, Mario Marcondes, Willem Overwijk, Venkata Lokesh Battula   +7 more
openaire   +1 more source